Navigation Links
Investigational anti-restenosis drug pimecrolimus disappoints
Date:3/31/2008

CHICAGO, Ill. (March 31, 2008) A new medication that researchers had hoped would reduce the risk of arterial renarrowing after stenting has turned in a disappointing performance in a multicenter clinical trial, but the multi-reservoir stent that was used to deliver the drug is still considered promising.

Pimecrolimus, an anti-inflammatory medication, was expected to reduce arterial inflammation and, therefore, the overgrowth of scar tissue, or neointimal hyperplasia, that causes in-stent restenosis. Instead, patients treated with pimecrolimus-eluting stents fared far worse than patients treated with stents that delivered a combination of pimecrolimus and paclitaxel, or paclitaxel alone, according to the Randomized, Multi-Center Study of the Pimecrolimus-Eluting and Pimecrolimus/Paclitaxel-Eluting Coronary Stent System in Patients with De Novo Lesions of the Native Coronary Arteries (GENESIS). Paclitaxel is also an anti-restenosis medication, but it works by inhibiting cell division, rather than by reducing arterial inflammation.

The GENESIS study was terminated early by its sponsors. The data gathered to that point are being reported today in a Late-Breaking Clinical Trials session at the SCAI Annual Scientific Sessions in Partnership with ACC i2 Summit (SCAI-ACCi2) in Chicago. SCAI-ACCi2 is a scientific meeting for practicing cardiovascular interventionalists sponsored by the Society for Cardiovascular Angiography and Interventions (SCAI) in partnership with the American College of Cardiology (ACC).

Despite pre-clinical data suggesting marked efficacy of pimecrolimus in suppressing neointimal hyperplasia, the extent of tissue growth and resulting rates of target vessel revascularization at six months were high in patients treated with this drug, said Stefan Verheye, MD, PhD, co-director of the catheterization laboratories at Antwerp Cardiovascular Center, ZNA Middelheim Hospital, Antwerp, Belgium.

The GENESIS study was als
'/>"/>

Contact: Kathy Boyd David
pr@scai.org
717-422-1181
Weber Shandwick Worldwide
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Investigational drug tested for preventing muscle fiber death in muscular dystrophy
2. Enrollment completed in 2 pivotal phase III studies of the investigational cancer drug vandetanib
3. New Drug Application Submitted to FDA for Investigational Analgesic Tapentadol Immediate Release Tablets
4. UCB Announces Positive Results From Phase II Clinical Trial of Investigational Anti-Epilepsy Drug Brivaracetam
5. SGX Pharmaceuticals Submits Investigational New Drug Application for SGX523, a Highly Potent, Selective, Orally Bioavailable cMET Inhibitor
6. MetaCure(TM) Launches Investigational Study of Gastric Stimulator for Patients With Type 2 Diabetes Who are Overweight
7. Abbotts Investigational SIMCOR(R) Offers Comparable LDL Lowering to Simvastatin and Significantly Raises HDL and Lowers Triglycerides in Phase III Study
8. Dynavax and Merck & Co., Inc. Announce Partnership to Develop HEPLISAV(TM), an Investigational Hepatitis B Vaccine Currently in Phase 3
9. Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody
10. Supratek Pharma Inc. announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for SP1049C for the treatment of metastatic adenocarcinoma of the upper gastrointestinal tract
11. Accentia announces investigational new drug application for Revimmune for refractory MS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2014)... 12, 2014 Sean Francis, owner of the Kawartha ... challenges to his clients. He’s also known for his support of ... a way to combine the two and is excited to announce ... the Boys and Girls Club. , The funds are the result ... June 23rd. Francis sent out emails and asked his clients to ...
(Date:7/12/2014)... For those who are unfamiliar with enzymes, they are ... in food. The enzymes literally break up the vitamins and ... absorbed by human bodies. According Dr. Henry Balzani, Medical Consultant ... food is the cause of many gastrointestinal health issues. ... DelPresto, a mother of 3 who is passionate about fitness ...
(Date:7/12/2014)... Lake City, Utah (PRWEB) July 12, 2014 ... spotlighted two types of startups, with awards being bestowed ... new emphasis spotlighted Utah’s outstanding entrepreneur community with recognition ... proving a sustainable model with incoming revenue. , 25 ... from across the state that are under 5 years ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 Restore My ... Sen and Samantha Pearson, a couple boasting very impressive ... launch Restore My Vision Today as a way to ... ophthalmologists have become in their respective patients’ treatments ... privy to a “secret” trove of pertinent information relevant ...
(Date:7/11/2014)... Recently, MagicQuinceaneraDresses.com, the popular online supplier ... of 2014 Quinceanera dresses . The company’s new ... look fashionable without paying a large amount of money. ... 57% off. , The company’s online shop has become ... special occasion outfits. In addition to exquisite Quinceanera dresses, ...
Breaking Medicine News(10 mins):Health News:Kawartha Lakes Fit Body Boot Camp’s Successful Fat Loss Challenge Results in $2,000 to Boys and Girls Club 2Health News:Kawartha Lakes Fit Body Boot Camp’s Successful Fat Loss Challenge Results in $2,000 to Boys and Girls Club 3Health News:New Super Digestive Enzyme, DZ10, Supercharges The Digestion Process 2Health News:SquareHook is Recognized for UVEF 25 Businesses Under 5 Years-Watch Out 2Health News:Restore My Vision Today | Groundbreaking Book Reveals How To Restore Your Vision Without The Use of Glasses – Vinamy 2Health News:Restore My Vision Today | Groundbreaking Book Reveals How To Restore Your Vision Without The Use of Glasses – Vinamy 3Health News:Cheap Quinceanera Dresses Now Available At MagicQuinceaneraDresses.com 2
... 1 When Madonna sets out to adopt a child, ... people are being introduced to Malawi -- a small impoverished ... orphaned children range from 500,000 to over a million, help ... are raised in nurturing homes, with a mother and siblings, ...
... Honors Award(TM)RIDGEFIELD, Conn., April 1 Boehringer ... Association of Diversity Councils with the organization,s ... award recognizes the outstanding contributions of the ... lead diversity processes in their organizations and ...
... Pro:Idiom , Enable MSOs to Conveniently Deliver HD ... R.L. Drake , an American cable TV equipment ... solutions for over 65 years, has checked in as ... cable operators in the United States and Canada. ...
... exchange technology gives patients initial breast cancer screening ... unit FARMERVILLE, La., April 1 A breakthrough ... first time to over-40 women who live in ... http://www.newscom.com/cgi-bin/prnh/20090401/NY92660 ) ...
... with vascular birthmarks around the eye, even partial blockage ... amblyopia. Now a simple test can detect early ... vision testing, reports a study in the April issue ... http://www.elsevier.com/locate/ajo ) published by Elsevier. , Led by Dr. ...
... it Takes to Form a New Habit; Lack of Motivation ... Conn., April 1 According to ... brand bottled water, the number one bottled water brand in ... months or longer to form a new habit. However, experts ...
Cached Medicine News:Health News:In Malawi, Adoption is Not Enough 2Health News:Boehringer Ingelheim Recognized For Diversity And Inclusion Efforts 2Health News:Drake Nabs 'Suite Deal' as Distributor of Pro:Idiom(R) Hospitality Solution to U.S. and Canadian Cable Operators 2Health News:New Mobile Mammography Unit Offers Residents of Rural Northern Louisiana First-Ever Access to Free Breast Cancer Screening Exams 2Health News:New Mobile Mammography Unit Offers Residents of Rural Northern Louisiana First-Ever Access to Free Breast Cancer Screening Exams 3Health News:New Mobile Mammography Unit Offers Residents of Rural Northern Louisiana First-Ever Access to Free Breast Cancer Screening Exams 4Health News:Test allows early detection of vision problems in infants with hemangiomas of eyelids 2Health News:Video: New Survey Reveals Misconceptions About Forming New Habits 2Health News:Video: New Survey Reveals Misconceptions About Forming New Habits 3Health News:Video: New Survey Reveals Misconceptions About Forming New Habits 4
(Date:7/10/2014)... 2014  Major advances in radiation therapy and ... highlighted in a three-day Oncology Summit taking place ... 2014.  Renowned national and international cancer experts from seven ... exchange knowledge on modern technologies making treatment for ... The Summit will address a wide ...
(Date:7/10/2014)... SAN DIEGO , July 10, 2014  RESMED INC. ... report its fourth quarter and fiscal year ended June 30, ... York Stock Exchange market close. A press release with ResMed,s ... and the company will host a webcast to discuss operating ... scheduled to begin at 1:30 p.m. US Pacific Time and ...
(Date:7/10/2014)...  Decision Resources Group finds that while more ... are willing to prescribe Durata,s Dalvance (dalbavancin) and ... OPAT, approximately two-thirds of the respondents reported a ... inpatients. However, our findings indicate that nearly two-thirds ... OPAT following hospital discharge, and most are discharged ...
Breaking Medicine Technology:Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3
... 2 Questcor Pharmaceuticals, Inc . (Nasdaq: QCOR ) announced ... on Thursday, June 10, 2010 at The Grand Hyatt Hotel in ... Chief Executive Officer, will discuss the Company,s business strategy and historical financial performance ... , , ...
... CUPERTINO, Calif. , June 1 DURECT Corporation (Nasdaq: DRRX ) ... be presenting at the Jefferies Global Life Sciences Conference on Thursday, June 10 ... the Grand Hyatt Hotel in New York .   , ... (Logo:   http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) , , ...
Cached Medicine Technology:Questcor to Present at the Jefferies 2010 Global Life Sciences Conference 2DURECT to Present at the Jefferies Global Life Sciences Conference 2
Double Ended Occluders...
Double Ended Occluders...
Designed to provide occlusion while permitting observation of the eye. Helpful to determine if only one eye is deviating. Approximately 9 inches long....
Short handle occluders are about 6 inches long....
Medicine Products: